REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy | AVESİS

Ege Üniversitesi Akademik Veri Yönetim Sistemi

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy

Atıf İçin Kopyala

Perol M., Ciuleanu T., Arrieta O., Prabhash K., Syrigos K. N. , Goeksel T. , ...Daha Fazla

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

Cilt numarası: 32
Basıldığı Şehir: Illinois
Basıldığı Ülke: Amerika Birleşik Devletleri